The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 25, 2009
Filed:
Oct. 07, 2003
Marie-helene Blondelet-rouault, Orsay, FR;
Helene Dominguez, Avignon, FR;
Emmanuelle Darbon-rongere, Voisins le Bretonneux, FR;
Claude Gerbaud, Gagny, FR;
Anne Gondran, Paris, FR;
Fatma Karray, Bures sur Yvette, FR;
Patricia Lacroix, Le Perreux, FR;
Nathalie Oestreicher-mermet-bouvier, Clamart, FR;
Pernodet Jean-luc, Cachan, FR;
Karine Tuphile, Caluire, FR;
Marie-Helene Blondelet-Rouault, Orsay, FR;
Helene Dominguez, Avignon, FR;
Emmanuelle Darbon-Rongere, Voisins le Bretonneux, FR;
Claude Gerbaud, Gagny, FR;
Anne Gondran, Paris, FR;
Fatma Karray, Bures sur Yvette, FR;
Patricia Lacroix, Le Perreux, FR;
Nathalie Oestreicher-Mermet-Bouvier, Clamart, FR;
Pernodet Jean-Luc, Cachan, FR;
Karine Tuphile, Caluire, FR;
Aventis Pharma S., Antony, FR;
Centre National de la Recherche Scientifique, Paris, FR;
Abstract
The present invention relates to the isolation and identification of novel genes of the biosynthetic pathway for spiramycins and to novel polypeptides involved in this biosynthesis. The invention also relates to a method for producing these polypeptides. It also relates to the use of these genes for the purpose of increasing the levels of production and the purity of the spiramycin produced. The invention relates in particular to a microorganism which produces spiramycin I but which does not produce spiramycin II and III, and to the use of such a microorganism. The invention also relates to the use of the genes of the biosynthetic pathway for spiramycins for constructing mutants which can lead to the synthesis of novel antibiotics or to derived forms of spiramycins. The invention also relates to the molecules produced through the expression of these genes and to pharmacologically active compositions of a molecule produced through the expression of such genes.